The Manila Times

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Enceph…

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Las Vegas News on MSN

The science behind why we dream and what it means

For centuries, humans have marveled at the strange theater of their nightly visions. We wake with fragments of impossible ...
TMCnet

Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
JCN Newswire

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...